FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089089100> ?p ?o ?g. }

• W3089089100 endingPage "623" @default.
• W3089089100 startingPage "619" @default.
• W3089089100 abstract "Purpose To compare rates of procedural intervention for arthrofibrosis following anterior cruciate ligament reconstruction (ACLR) among patients who were not prescribed any pharmacologic thromboprophylaxis compared with patients who were prescribed aspirin and to patients who were prescribed other agents. Methods A search of a national insurance claims database was performed to identify all patients who underwent ACLR from 2007 to 2017 who were active within the database at a minimum of 6 months before and 18 months after their surgery. The primary outcome studied was a subsequent procedure for arthrofibrosis, manipulation under anesthesia, and lysis of adhesions (MUA/LOA). Patients who filled a prescription for aspirin, low-molecular weight heparin, direct factor Xa inhibitors, fondaparinux, and warfarin within 2 days after their surgery were included and those who filled a prescription within 3 months before surgery were excluded. Thromboprophylaxis status was defined as no thromboprophylaxis, aspirin, and any agent other than aspirin. Logistic regression analysis was performed to determine the association between prophylaxis status and MUA/LOA. Results Of the 14,081 patients in our final surgical population, 191 patients had MUA/LOA and 13,890 patients did not. In total, 499 patients were prescribed pharmacologic prophylaxis. Rates of MUA/LOA across groups were 1.3% in the group with no thromboprophylaxis, 1.9% in the group prescribed aspirin, and 4.3% in the group prescribed any agent other than aspirin. Only the group prescribed an agent other than aspirin was significantly associated with subsequent procedure for arthrofibrosis (odds ratio 2.6, 95% confidence interval 1.3-4.8, P = .004). Conclusions Patients who were prescribed a pharmacologic agent other than aspirin had a 2.6 times greater likelihood of requiring a procedural intervention for arthrofibrosis following ACLR compared with patients who were not prescribed a thromboprophylaxis agent Level of Evidence III, Retrospective Cohort Study To compare rates of procedural intervention for arthrofibrosis following anterior cruciate ligament reconstruction (ACLR) among patients who were not prescribed any pharmacologic thromboprophylaxis compared with patients who were prescribed aspirin and to patients who were prescribed other agents. A search of a national insurance claims database was performed to identify all patients who underwent ACLR from 2007 to 2017 who were active within the database at a minimum of 6 months before and 18 months after their surgery. The primary outcome studied was a subsequent procedure for arthrofibrosis, manipulation under anesthesia, and lysis of adhesions (MUA/LOA). Patients who filled a prescription for aspirin, low-molecular weight heparin, direct factor Xa inhibitors, fondaparinux, and warfarin within 2 days after their surgery were included and those who filled a prescription within 3 months before surgery were excluded. Thromboprophylaxis status was defined as no thromboprophylaxis, aspirin, and any agent other than aspirin. Logistic regression analysis was performed to determine the association between prophylaxis status and MUA/LOA. Of the 14,081 patients in our final surgical population, 191 patients had MUA/LOA and 13,890 patients did not. In total, 499 patients were prescribed pharmacologic prophylaxis. Rates of MUA/LOA across groups were 1.3% in the group with no thromboprophylaxis, 1.9% in the group prescribed aspirin, and 4.3% in the group prescribed any agent other than aspirin. Only the group prescribed an agent other than aspirin was significantly associated with subsequent procedure for arthrofibrosis (odds ratio 2.6, 95% confidence interval 1.3-4.8, P = .004). Patients who were prescribed a pharmacologic agent other than aspirin had a 2.6 times greater likelihood of requiring a procedural intervention for arthrofibrosis following ACLR compared with patients who were not prescribed a thromboprophylaxis agent" @default.
• W3089089100 created "2020-10-01" @default.
• W3089089100 creator A5010675489 @default.
• W3089089100 creator A5017708219 @default.
• W3089089100 creator A5020157057 @default.
• W3089089100 creator A5021860098 @default.
• W3089089100 creator A5031790968 @default.
• W3089089100 creator A5085867110 @default.
• W3089089100 date "2021-02-01" @default.
• W3089089100 modified "2023-09-24" @default.
• W3089089100 title "Pharmacologic Thromboprophylaxis Other Than Aspirin Is Associated With Increased Risk for Procedural Intervention for Arthrofibrosis After Anterior Cruciate Ligament Reconstruction" @default.
• W3089089100 cites W1764392715 @default.
• W3089089100 cites W1969892807 @default.
• W3089089100 cites W1990296912 @default.
• W3089089100 cites W2055717854 @default.
• W3089089100 cites W2069947000 @default.
• W3089089100 cites W2110683830 @default.
• W3089089100 cites W2146500825 @default.
• W3089089100 cites W2153909186 @default.
• W3089089100 cites W2177961447 @default.
• W3089089100 cites W2255310938 @default.
• W3089089100 cites W2578077079 @default.
• W3089089100 cites W2588250073 @default.
• W3089089100 cites W2594143199 @default.
• W3089089100 cites W2734904293 @default.
• W3089089100 cites W2755283636 @default.
• W3089089100 cites W2768634702 @default.
• W3089089100 cites W2800729906 @default.
• W3089089100 cites W2885346167 @default.
• W3089089100 cites W2886283886 @default.
• W3089089100 cites W2891214991 @default.
• W3089089100 cites W2908031828 @default.
• W3089089100 cites W2938979766 @default.
• W3089089100 cites W2981160120 @default.
• W3089089100 doi "https://doi.org/10.1016/j.arthro.2020.09.019" @default.
• W3089089100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32976955" @default.
• W3089089100 hasPublicationYear "2021" @default.
• W3089089100 type Work @default.
• W3089089100 sameAs 3089089100 @default.
• W3089089100 citedByCount "6" @default.
• W3089089100 countsByYear W30890891002022 @default.
• W3089089100 crossrefType "journal-article" @default.
• W3089089100 hasAuthorship W3089089100A5010675489 @default.
• W3089089100 hasAuthorship W3089089100A5017708219 @default.
• W3089089100 hasAuthorship W3089089100A5020157057 @default.
• W3089089100 hasAuthorship W3089089100A5021860098 @default.
• W3089089100 hasAuthorship W3089089100A5031790968 @default.
• W3089089100 hasAuthorship W3089089100A5085867110 @default.
• W3089089100 hasConcept C126322002 @default.
• W3089089100 hasConcept C141071460 @default.
• W3089089100 hasConcept C156957248 @default.
• W3089089100 hasConcept C2776301958 @default.
• W3089089100 hasConcept C2776877702 @default.
• W3089089100 hasConcept C2777595943 @default.
• W3089089100 hasConcept C2777628954 @default.
• W3089089100 hasConcept C2779161974 @default.
• W3089089100 hasConcept C2780868729 @default.
• W3089089100 hasConcept C2908647359 @default.
• W3089089100 hasConcept C2991741193 @default.
• W3089089100 hasConcept C3017871827 @default.
• W3089089100 hasConcept C42219234 @default.
• W3089089100 hasConcept C44249647 @default.
• W3089089100 hasConcept C71924100 @default.
• W3089089100 hasConcept C99454951 @default.
• W3089089100 hasConceptScore W3089089100C126322002 @default.
• W3089089100 hasConceptScore W3089089100C141071460 @default.
• W3089089100 hasConceptScore W3089089100C156957248 @default.
• W3089089100 hasConceptScore W3089089100C2776301958 @default.
• W3089089100 hasConceptScore W3089089100C2776877702 @default.
• W3089089100 hasConceptScore W3089089100C2777595943 @default.
• W3089089100 hasConceptScore W3089089100C2777628954 @default.
• W3089089100 hasConceptScore W3089089100C2779161974 @default.
• W3089089100 hasConceptScore W3089089100C2780868729 @default.
• W3089089100 hasConceptScore W3089089100C2908647359 @default.
• W3089089100 hasConceptScore W3089089100C2991741193 @default.
• W3089089100 hasConceptScore W3089089100C3017871827 @default.
• W3089089100 hasConceptScore W3089089100C42219234 @default.
• W3089089100 hasConceptScore W3089089100C44249647 @default.
• W3089089100 hasConceptScore W3089089100C71924100 @default.
• W3089089100 hasConceptScore W3089089100C99454951 @default.
• W3089089100 hasIssue "2" @default.
• W3089089100 hasLocation W30890891001 @default.
• W3089089100 hasOpenAccess W3089089100 @default.
• W3089089100 hasPrimaryLocation W30890891001 @default.
• W3089089100 hasRelatedWork W1995900004 @default.
• W3089089100 hasRelatedWork W1998931526 @default.
• W3089089100 hasRelatedWork W2017906829 @default.
• W3089089100 hasRelatedWork W2053627978 @default.
• W3089089100 hasRelatedWork W2058807493 @default.
• W3089089100 hasRelatedWork W2131430171 @default.
• W3089089100 hasRelatedWork W2602431682 @default.
• W3089089100 hasRelatedWork W2619710086 @default.
• W3089089100 hasRelatedWork W2945399567 @default.
• W3089089100 hasRelatedWork W3084260015 @default.
• W3089089100 hasVolume "37" @default.
• W3089089100 isParatext "false" @default.
• W3089089100 isRetracted "false" @default.
• W3089089100 magId "3089089100" @default.

• next